HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HAIXI PHARMA

198.400

+6.4003.33%

Volume:85.27K

Turnover:16.92M

Market Cap:15.62B

PE:66.54

High:201.800

Open:196.000

Low:192.100

Close:192.000

52wk High:302.400

52wk Low:97.500

Shares:78.71M

HK Float Shares:78.71M

Volume Ratio:0.90

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(LYR):2.982

ROE:16.58%

ROA:9.23%

PB:8.00

PE(LYR):66.54

PS:22.49

Loading ...

Overview Company News Filings

Fujian Haixi Pharmaceuticals publishes 2025 annual report

HAIXI PHARMA Proposes Adoption of H-Share Incentive Scheme

Fujian Haixi Pharma proposes H-share incentive scheme funded by existing shares

Stock Track | Haixi Pharma Soars 7.66% Intraday on Broker Initiation, Strong Financials and Positive Clinical Data

Haixi Pharma Adopts Full Electronic Dissemination of Corporate Communications

Bulletin Express

Haixi Pharma Shifts to Fully Electronic Distribution of Corporate Communications

Bulletin Express

Stock Track | Haixi Pharma Soars 5.06% Intraday on Broker Buy Rating and Strong Drug Pipeline Progress

Stock Track | Haixi Pharma Soars 14.56% Intraday on First Broker Coverage and Pipeline Optimism

HAIXI PHARMA Surges Over 7% to Record High as HXP056 Nears Key Data Milestone

HAIXI PHARMA Shares Surge Over 4% as HXP056 Shows Significant Inhibition of Fundus Leakage; Potential to Reshape wAMD Treatment Landscape Upon Success

HAIXI PHARMA Maintains 78.71 Million Issued Shares in March 2026; Public Float Meets 25% Threshold

Bulletin Express

Three Undiscovered Asian Gems To Enhance Your Portfolio

Simply Wall St.

HAIXI PHARMA Shares Surge Over 8% Following Strong FY2025 Results

HAIXI PHARMA Reports 2025 Financial Results with Net Profit Jumping 30.09%

Haixi Pharma posts 30% profit jump in 2025, buoyed by generic drug sales and IPO proceeds

Bulletin Express

HAIXI PHARMA Shares Surge Over 4% in Morning Session as HXP056 Completes Phase I Enrollment and Initiates Phase II Study

Haixi Pharma completes Phase I enrollment for first-in-class oral wAMD drug HXP056; Phase II study underway

Bulletin Express

HAIXI PHARMA's Oral wAMD Drug Candidate HXP056 Concludes Phase I Enrollment and Advances to Phase II

Fujian Haixi Pharma starts Phase 2 China trial of HXP056 for wet age-related macular degeneration

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/02637/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"02637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"HAIXI PHARMA","latestPrice":198.4,"timestamp":1789546126006,"preClose":192,"halted":0,"volume":85268,"delay":0,"changeRate":0.03333333333333336,"floatShares":78707270,"shares":78707270,"eps":2.9816815721346193,"marketStatus":"Not Yet Opened","change":6.4,"latestTime":"09-16 16:08:46","open":196,"high":201.8,"low":192.1,"amount":16923890,"amplitude":0.050521,"askPrice":199.5,"askSize":50,"bidPrice":198.4,"bidSize":450,"shortable":3,"etf":0,"ttmEps":2.334819201859261,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":0,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":192,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"volumeRatio":0.896237,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","floatShares":78707270,"roa":"9.23%","roe":"16.58%","lyrEps":2.981682,"volumeRatio":0.896237,"shares":78707270,"dividePrice":0,"high":201.8,"amplitude":0.050521,"preClose":192,"low":192.1,"week52Low":97.5,"pbRate":"8.00","psRate":"22.49","week52High":302.4,"institutionHeld":0,"latestPrice":198.4,"committee":0.8,"eps":2.9816815721346193,"divideRate":0,"volume":85268,"delay":0,"ttmEps":2.334819201859261,"open":196,"prevYearClose":136,"prevWeekClose":193,"prevMonthClose":192,"prevQuarterClose":180,"fiveDayClose":192.3,"twentyDayClose":200,"sixtyDayClose":160},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02637\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-30","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1781107200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02637","date":"2026-09-15","current":84.9871,"percent":0.864865,"low":41.43616,"twenty":68.545808,"median":72.645218,"eighty":81.246438,"high":108.687128,"avg":74.536737,"sd":9.343152,"marketCap":15111795840},"quantilePoints":[{"date":"2025-10-16","current":41.43616,"twenty":41.43616,"median":41.43616,"eighty":41.43616,"marketCap":6150186077},{"date":"2025-10-24","current":58.044665,"twenty":53.788314,"median":54.742854,"eighty":58.044665,"marketCap":8618446065},{"date":"2025-10-31","current":63.409996,"twenty":54.11413,"median":58.177187,"eighty":60.582738,"marketCap":9429130946},{"date":"2025-11-07","current":65.038519,"twenty":55.071217,"median":59.875924,"eighty":63.533346,"marketCap":9665252756},{"date":"2025-11-14","current":69.713569,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"marketCap":10389359640},{"date":"2025-11-21","current":66.575785,"twenty":58.2567,"median":64.026746,"eighty":69.208194,"marketCap":9917116020},{"date":"2025-11-28","current":68.072175,"twenty":59.478322,"median":65.807152,"eighty":68.767812,"marketCap":10176850011},{"date":"2025-12-05","current":68.42835,"twenty":59.854834,"median":66.893861,"eighty":68.767812,"marketCap":10247686554},{"date":"2025-12-12","current":69.403659,"twenty":60.326406,"median":67.279459,"eighty":69.361692,"marketCap":10412971821},{"date":"2025-12-19","current":69.502155,"twenty":61.237436,"median":67.861589,"eighty":69.423358,"marketCap":10452325456},{"date":"2025-12-24","current":72.521094,"twenty":61.537644,"median":68.055113,"eighty":69.462757,"marketCap":10940310530},{"date":"2026-01-02","current":68.547,"twenty":62.032842,"median":68.254334,"eighty":69.697511,"marketCap":10381488913},{"date":"2026-01-09","current":76.256401,"twenty":63.533346,"median":68.54394,"eighty":70.33117,"marketCap":11577839417},{"date":"2026-01-16","current":83.450154,"twenty":64.030428,"median":68.594109,"eighty":71.180851,"marketCap":12711224105},{"date":"2026-01-23","current":75.203122,"twenty":64.243828,"median":68.851274,"eighty":73.407226,"marketCap":11444037058},{"date":"2026-01-30","current":72.029156,"twenty":65.345972,"median":69.26967,"eighty":73.580372,"marketCap":11011147073},{"date":"2026-02-06","current":69.741329,"twenty":66.631937,"median":69.18814,"eighty":73.524909,"marketCap":10688447266},{"date":"2026-02-13","current":69.700471,"twenty":66.864009,"median":69.376262,"eighty":73.289662,"marketCap":10743542355},{"date":"2026-02-20","current":69.085102,"twenty":66.878935,"median":69.376262,"eighty":72.984771,"marketCap":10633352177},{"date":"2026-02-27","current":72.331605,"twenty":67.046254,"median":69.403659,"eighty":72.584608,"marketCap":11255139610},{"date":"2026-03-06","current":63.89376,"twenty":67.046254,"median":69.448144,"eighty":72.584608,"marketCap":9862020931},{"date":"2026-03-13","current":75.4784,"twenty":67.193436,"median":69.633279,"eighty":73.562991,"marketCap":11703771049},{"date":"2026-03-20","current":69.956787,"twenty":67.26348,"median":69.715081,"eighty":73.483508,"marketCap":10806508171},{"date":"2026-03-27","current":78.768036,"twenty":67.31702,"median":69.741329,"eighty":73.616705,"marketCap":12136661034},{"date":"2026-04-02","current":69.050489,"twenty":67.448055,"median":69.756887,"eighty":73.953025,"marketCap":13907574609},{"date":"2026-04-10","current":75.734842,"twenty":67.617502,"median":69.89051,"eighty":74.51958,"marketCap":15371529831},{"date":"2026-04-17","current":75.664292,"twenty":67.861589,"median":70.029272,"eighty":74.51958,"marketCap":15363659104},{"date":"2026-04-24","current":92.094347,"twenty":68.038051,"median":70.361759,"eighty":74.892793,"marketCap":18700847352},{"date":"2026-04-30","current":101.138303,"twenty":68.06535,"median":70.518529,"eighty":75.515578,"marketCap":20542597470},{"date":"2026-05-08","current":91.134409,"twenty":68.133872,"median":70.614497,"eighty":76.472636,"marketCap":18574915720},{"date":"2026-05-15","current":84.578883,"twenty":68.178204,"median":70.813553,"eighty":78.193464,"marketCap":17284116492},{"date":"2026-05-22","current":93.496946,"twenty":68.295676,"median":71.108793,"eighty":80.407586,"marketCap":19062900794},{"date":"2026-05-29","current":86.09458,"twenty":68.386305,"median":71.340959,"eighty":80.936301,"marketCap":17614687026},{"date":"2026-06-05","current":72.717092,"twenty":68.497704,"median":72.103769,"eighty":80.766638,"marketCap":14899286211},{"date":"2026-06-12","current":67.961351,"twenty":68.497704,"median":71.340959,"eighty":80.580489,"marketCap":13915445336},{"date":"2026-06-18","current":66.149737,"twenty":68.365282,"median":71.108793,"eighty":80.547429,"marketCap":13577004075},{"date":"2026-06-26","current":64.123676,"twenty":68.103023,"median":70.813553,"eighty":80.470686,"marketCap":13096889728},{"date":"2026-07-03","current":76.78307,"twenty":68.156523,"median":70.813553,"eighty":80.277662,"marketCap":15694229638},{"date":"2026-07-10","current":79.190679,"twenty":68.212992,"median":71.108793,"eighty":80.277662,"marketCap":16166473258},{"date":"2026-07-17","current":71.84101,"twenty":68.34426,"median":71.590985,"eighty":79.86919,"marketCap":14718259490},{"date":"2026-07-24","current":70.518964,"twenty":68.451468,"median":71.287767,"eighty":79.796901,"marketCap":14450654772},{"date":"2026-07-31","current":65.554893,"twenty":68.149296,"median":70.906272,"eighty":79.747346,"marketCap":13458943170},{"date":"2026-08-07","current":75.261161,"twenty":68.149296,"median":71.19828,"eighty":79.190679,"marketCap":15481720009},{"date":"2026-08-14","current":78.261297,"twenty":68.185431,"median":71.340959,"eighty":78.768036,"marketCap":16119248896},{"date":"2026-08-21","current":76.639812,"twenty":68.323237,"median":72.054899,"eighty":79.190679,"marketCap":15820161270},{"date":"2026-08-28","current":74.907011,"twenty":68.42835,"median":72.201471,"eighty":78.768036,"marketCap":15465978555},{"date":"2026-09-04","current":89.46632,"twenty":68.54394,"median":72.352576,"eighty":79.884165,"marketCap":15686358911},{"date":"2026-09-11","current":86.521471,"twenty":68.545014,"median":72.521094,"eighty":80.616434,"marketCap":15190503110},{"date":"2026-09-15","current":86.087181,"twenty":68.545808,"median":72.645218,"eighty":81.246438,"marketCap":15111795840}],"updateTime":1789584068802},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02637\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2631514990","title":"Fujian Haixi Pharmaceuticals publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2631514990","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631514990?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:55","pubTimestamp":1777467349,"startTime":"0","endTime":"0","summary":"HXPharma published its 2025 annual report, highlighting continued expansion of commercial footprint in China alongside a dual-track strategy combining generics with in-house innovative R&D.Portfolio reached 15 NMPA-cleared generic drugs, supported by distribution coverage of over 18,000 hospitals and medical institutions.National volume-based procurement products remained main growth drivers, led by Haihuitong and Anbili.Lead oncology candidate C019199 is slated to start Phase III osteosarcoma trials in 1H 2026, positioning it as potential first-in-class therapy.Oral retinal disease candidate HXP056 moved into Phase II in 4Q 2025, with US and China studies planned in 2026 for nAMD and DME.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL5CrSfQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143765846","title":"HAIXI PHARMA Proposes Adoption of H-Share Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1143765846","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143765846?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:52","pubTimestamp":1777467143,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) has announced that on April 29, 2026, the board of directors passed a resolution proposing the adoption of a share incentive plan applicable to the company's H-shares. The share...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631514316","title":"Fujian Haixi Pharma proposes H-share incentive scheme funded by existing shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2631514316","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631514316?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:49","pubTimestamp":1777466955,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals board moved to adopt a share incentive scheme for H shares on April 29, 2026.Plan will be funded by existing shares, not new share issuance.Implementation requires shareholder approval via special resolution at upcoming annual general meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLRBdwQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119193958","title":"Stock Track | Haixi Pharma Soars 7.66% Intraday on Broker Initiation, Strong Financials and Positive Clinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1119193958","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119193958?lang=en_us&edition=fundamental","pubTime":"2026-04-29 10:00","pubTimestamp":1777428000,"startTime":"0","endTime":"0","summary":"Haixi Pharma's stock surged 7.66% during intraday trading on Wednesday, staging a significant rebound.The movement follows the initiation of coverage by Shenwan Hongyuan with a Buy rating and a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137771673","title":"Haixi Pharma Adopts Full Electronic Dissemination of Corporate Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=1137771673","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137771673?lang=en_us&edition=fundamental","pubTime":"2026-04-28 21:24","pubTimestamp":1777382666,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma) confirmed a transition to electronic delivery for all future corporate communications in line with Rule 2.07A of the Hong Kong Stock Exchange...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165703728","title":"Haixi Pharma Shifts to Fully Electronic Distribution of Corporate Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=1165703728","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165703728?lang=en_us&edition=fundamental","pubTime":"2026-04-28 21:23","pubTimestamp":1777382623,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma, 02637) has announced that, effective 30 April 2026, all future corporate communications will be disseminated exclusively via electronic channels...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141705590","title":"Stock Track | Haixi Pharma Soars 5.06% Intraday on Broker Buy Rating and Strong Drug Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1141705590","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141705590?lang=en_us&edition=fundamental","pubTime":"2026-04-28 09:48","pubTimestamp":1777340905,"startTime":"0","endTime":"0","summary":"Haixi Pharma's stock surged 5.06% during intraday trading on Tuesday, continuing its strong performance this year.The price movement follows Shenwan Hongyuan's initiation of coverage on the company...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120458534","title":"Stock Track | Haixi Pharma Soars 14.56% Intraday on First Broker Coverage and Pipeline Optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=1120458534","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120458534?lang=en_us&edition=fundamental","pubTime":"2026-04-27 09:51","pubTimestamp":1777254687,"startTime":"0","endTime":"0","summary":"Haixi Pharma's stock surged 14.56% during intraday trading on Monday, marking a significant upward movement.The rally was primarily driven by Shenwan Hongyuan's first-ever coverage of the company,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113832302","title":"HAIXI PHARMA Surges Over 7% to Record High as HXP056 Nears Key Data Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=1113832302","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113832302?lang=en_us&edition=fundamental","pubTime":"2026-04-24 10:38","pubTimestamp":1776998304,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) rose more than 7%, reaching an intraday high of HKD 230.4, a new record. At the time of writing, the stock was up 7.42% to HKD 228.8, with a turnover of HKD 53.3445 million. The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1191","VXUS","BK4588","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176595853","title":"HAIXI PHARMA Shares Surge Over 4% as HXP056 Shows Significant Inhibition of Fundus Leakage; Potential to Reshape wAMD Treatment Landscape Upon Success","url":"https://stock-news.laohu8.com/highlight/detail?id=1176595853","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176595853?lang=en_us&edition=fundamental","pubTime":"2026-04-17 11:10","pubTimestamp":1776395424,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) rose more than 4%. At the time of writing, the stock was up 3.8%, trading at HK$196.6 with a turnover of HK$28.8643 million. The company previously announced that its innovative...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191","BK4588","IPOS","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112407237","title":"HAIXI PHARMA Maintains 78.71 Million Issued Shares in March 2026; Public Float Meets 25% Threshold","url":"https://stock-news.laohu8.com/highlight/detail?id=1112407237","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112407237?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:04","pubTimestamp":1775639074,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 31 March 2026, confirming no changes in either authorised or...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624828520","title":"Three Undiscovered Asian Gems To Enhance Your Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2624828520","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624828520?lang=en_us&edition=fundamental","pubTime":"2026-04-02 12:03","pubTimestamp":1775102626,"startTime":"0","endTime":"0","summary":"As geopolitical tensions and energy price volatility ripple through global markets, Asian equities are navigating a complex landscape with both challenges and opportunities. Amidst this backdrop, the S&P MidCap 400 and Russell 2000 indexes have shown resilience, highlighting the potential for small-cap stocks to thrive in uncertain times. In such an environment, identifying strong fundamentals and growth potential can be key to uncovering undiscovered gems that might enhance a diversified...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2637/fujian-haixi-pharmaceuticals-shares/news/three-undiscovered-asian-gems-to-enhance-your-portfolio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2637/fujian-haixi-pharmaceuticals-shares/news/three-undiscovered-asian-gems-to-enhance-your-portfolio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108606328","title":"HAIXI PHARMA Shares Surge Over 8% Following Strong FY2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1108606328","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108606328?lang=en_us&edition=fundamental","pubTime":"2026-04-01 10:20","pubTimestamp":1775010018,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) saw its shares rise more than 8% after the company reported its financial results for the fiscal year 2025. As of the latest update, the stock was up 8.06%, trading at HK$172.9,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","VXUS","BK4585","BK4588","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100804736","title":"HAIXI PHARMA Reports 2025 Financial Results with Net Profit Jumping 30.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100804736","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100804736?lang=en_us&edition=fundamental","pubTime":"2026-03-31 00:20","pubTimestamp":1774887615,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) has announced its financial results for 2025. The company reported revenue of approximately 582 million yuan, representing a year-on-year increase of 24.79%. Net profit reached...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184521353","title":"Haixi Pharma posts 30% profit jump in 2025, buoyed by generic drug sales and IPO proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=1184521353","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184521353?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:43","pubTimestamp":1774881832,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals (Haixi Pharma) reported solid full-year results for 2025, underpinned by robust growth in its generic drug portfolio and strengthened by fresh capital from its October...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148445511","title":"HAIXI PHARMA Shares Surge Over 4% in Morning Session as HXP056 Completes Phase I Enrollment and Initiates Phase II Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1148445511","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148445511?lang=en_us&edition=fundamental","pubTime":"2026-03-25 10:38","pubTimestamp":1774406316,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) saw its shares rise more than 4% during the morning trading session. At the time of writing, the stock was up 3.42%, trading at HKD 148, with a turnover of HKD 19.4604 million....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637","BK4588","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193673628","title":"Haixi Pharma completes Phase I enrollment for first-in-class oral wAMD drug HXP056; Phase II study underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1193673628","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193673628?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:21","pubTimestamp":1774344070,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma) announced the full enrollment of patients into both the single ascending dose and multiple ascending dose cohorts of its Phase I clinical trial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187639991","title":"HAIXI PHARMA's Oral wAMD Drug Candidate HXP056 Concludes Phase I Enrollment and Advances to Phase II","url":"https://stock-news.laohu8.com/highlight/detail?id=1187639991","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187639991?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:16","pubTimestamp":1774343796,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) announced that its innovative drug candidate HXP056, a potential first-in-class oral medication for hemorrhagic retinal diseases, has completed patient enrollment for the Phase I...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621605091","title":"Fujian Haixi Pharma starts Phase 2 China trial of HXP056 for wet age-related macular degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2621605091","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621605091?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:11","pubTimestamp":1774343471,"startTime":"0","endTime":"0","summary":"Haixi Pharmaceuticals said its oral wet age-related macular degeneration  candidate HXP056 has completed Phase 1 patient enrollment and has moved into a Phase 2 dose-expansion study in China.The company is positioning HXP056 as an oral alternative in retinal disease indications, which could broaden treatment access compared with injection-based care if later-stage trials support approval.Haixi Pharmaceuticals said the program is designed to support drug distribution to the retina, aiming to reduce development constraints that have limited oral approaches in this area.The company plans to use Phase 2 results to select an optimal dose to support a future Phase 3 study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL1N0ttT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":79,"code":"91000000","status":"200"}]}}